Prior research has shown that most of the resistant tumours remain ERα-positive and critically dependent on activity of this signalling axis, with activating ESR1 gene mutations occurring in 15–40% of advanced cancers [4,5,6,7]. The gene discussed is ESR1; the disease is cancer.